VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Polyphenol Combination.

Fiche publication

Date publication

juin 2021

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DELMAS Dominique , Dr PAIS DE BARROS Jean-Paul , Dr AIRES Virginie

Tous les auteurs :
Courtaut F, Scagliarini A, Aires V, Cornebise C, Pais de Barros JP, Olmiere C, Delmas D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34205419

Résumé

Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 retinal cells, a disruption of the VEGF receptors (VEGF-R)/caveolin-1 (Cav-1)/protein kinases pathway could be a target for counteracting VEGF secretion. We highlight that Resvega, a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation. Moreover, DNA ChIP analysis reveals that this combination prevents the interaction between AP-1 and and gene promoters. By these pathways, Resvega could present a potential interest as nutritional complementation against AMD.